Response to 'D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients' by Leguay et al Leukemia (2005) In their letter to the editor, Leguay et al 1 present the clinical and molecular characteristics of two patients affected by chronic myeloid leukemia (CML) and treated with imatinib. These two patients showed an aggressive clinical course: they developed resistance to the drug and died soon after the evolution to blast crisis (BC: one lymphoid, one myeloid). Sequencing analysis of the Abl catalytic domain of samples taken during relapse showed the presence of mutation D276G in both cases. Thus, the authors conclude that mutation D276G could be linked to an aggressive disease course and a rapid transformation to acute phase, associated with a particularly poor prognosis.
We recently published 2 a case report on a patient affected by Bcr/Abl p190 acute lymphoblastic leukemia (ALL) treated with imatinib who developed resistance to the drug and in whom mutation analysis revealed mutation D276G. This patient was diagnosed with ALL on April 2001, started standard chemotherapy regimen and obtained a complete cytogenetic remission (CCR), remaining positive for p190 at the molecular level. On August 2001, he started on imatinib 800 mg daily and remained in cytogenetic remission until January 2002 when bone marrow aspirate showed 70% blasts. He died on November 2002, despite receiving chemotherapy followed by autografting.
A second case of D276G mutation identified in our laboratory is a chronic phase (CP) CML patient who was diagnosed on March 1995. The patient started on imatinib, 400 mg daily, in January 2000. After 12 months of treatment, he showed only a minor cytogenetic response; thus, his dose was increased to 800 mg. He obtained a CCR after 6 months, but remained positive on PCR. Clonal mutational screening on a bone marrow sample, taken 3 months after the achievement of CCR (October 2001) , revealed the presence of mutation F359V on 6/10 clones analyzed. In a successive analysis (May 2003), mutation F359V was found to be present in 10/10 clones and mutation D276G in 2/10 clones. The patient subsequently lost the CCR but has not progressed to the accelerated phase (AP)/BC, although he developed additional cytological abnormalities.
Also, in the original description of D276G mutation, 3 the patient first developed a F359V mutation while in remission from a Ph þ ALL, and showed the D276G at the time of clinical relapse.
A further review of the literature available also identified a fifth case of Ph þ leukemia resistant to imatinib carrying mutation D276G 4 ; in this case also, the clinical course of the disease was aggressive, with D276G observed at the time of BC development.
Clinical data from these patients carrying mutation D276G show, in general, an aggressive course, according to what is suggested by Leguay and co-workers, with the D276G mutation detected at the time of disease progression in four out of five cases. However, in the analysis of these data, prudence is required. Two patients were affected by ALL; thus, their clinical course is not easily comparable with the CML patients; our second patient carried mutation D276G only in a fraction (20%) of the resistant clones; thus, the clinical characteristics of this patient could be linked to the most represented mutation (F359V). Moreover, mutation D276G was present as a double mutant with F359V, and it is known that these two mutations act via different molecular mechanisms; 5 thus, an additive effect cannot be ruled out. Finally, it is important to underline that at the moment, to our knowledge, there is no convincing molecular mechanism supporting the aggressive course of mutation D276G other than its increased kinetic activity. Most patients (more than 95%) with chronic myeloid leukemia (CML) express the BCR-ABL transcript with the b2a2 (e13a2) or b3a2 (e14a2) junctions corresponding to the major BCR gene breakpoint cluster region (M-BCR). We and others have reported that a small proportion of CML patients (1-2%), who have breakpoints that fall outside of the M-BCR in chromosome 22, give rise to a shortened BCR-ABL transcript with an e1a2 junction (m-BCR), e6a2, b2a3 (e13a3), b3a3 (e14a3) or longer BCR-ABL transcripts with an e19a2 (m-BCR) junction (Figure 1a ). The majority of these atypical transcripts encode fusion proteins that lack or retain different BCR domains, which could influence the clinical phenotype of the disease entity. 1 The clinical and hematologic features of eight additional patients with e8a2 BCR-ABL fusions transcripts have been recently reviewed 2 and, according to the authors, could be associated with a worse prognosis than M-BCR transcripts. An inverse correlation between the size of the BCR portion retained in the fusion protein and the aggressive behavior of the disease was suggested and thus BCR domains could attenuate the leukemic phenotype.
2 In this manuscript, we report for the first time to our knowledge, three additional CML patients with an e8a2 BCR-ABL fusion transcript treated with imatinib mesylate with a median follow-up of 34 months.
These cases (patients no. 1, 2 and 3) were diagnosed with CML in chronic phase based on typical peripheral blood findings and on standard karyotyping analyses indicating t(9;22)(q34;q11). The relevant clinical and biological data for the patients are given in Table 1 . In case no. 1, fluorescence in situ hybridization (FISH) analysis performed with dual color probes for BCR and ABL genes (LSI bcr/abl ES Dual Color Translocation Probe, VYSIS Downer's Grove, IL, USA) showed a typical M-BCR picture in 20 metaphases and 100 interphase nuclei (data not shown) which was different from the case previously described.
2 The first case (no. 1), a 40-year-old male patient, was referred to the Centre Hospitalier Lyon Sud hospital in July 2002 for hyperleukocytosis at 39 Â 10 9 /l with myelemia, discovered on a systematic peripheral blood analysis. After karyotyping analysis, imatinib was introduced in August 2002. The cases no. 2 and no. 3 were referred to the Saint Louis hospital in February 2002 and November 2002, and imatinib was introduced in March and December 2002, respectively. In all cases, multiplex RT-PCR performed for BCR-ABL at diagnosis showed an atypically large fragment that turned out to correspond, after direct sequencing, to an e8a2 fusion transcript with a 55 base pair (bp) insert that wholly matched an inverted sequence from ABL intron Ib (Figure 1a) . The monitoring of the minimal residual disease (MRD) was carried out using real-time RT-PCR 3 with specific forward primers, located close to the e8-BCR (Figure 1b) . The introduction of imatinib mesylate therapy at 400 mg/day allowed complete hematologic and cytogenetic responses at 6 months and a major molecular response in all cases, with a reduction of at least three logs of BCR-ABL transcript levels compared to the diagnosis, at a median follow-up of 34 months (range 30-39) (Figure 1b) . Of note, in cases no. 2 and no. 3, a major molecular response was obtained only after increasing the dosage of imatinib, suggesting that those patients may require higher doses (600 mg/day) of imatinib to achieve proper molecular response. Most of the previously described patients with an e8a2 BCR-ABL fusion transcript had thrombocytosis and seemed to be associated with worse prognosis.
2 None of the cases described here showed thrombocytosis (Table 1) . Moreover, none of the patients previously described, treated with interferon-a, achieved even a minor response; all of the cases treated with imatinib were alive at a median follow-up of 34 months, achieved complete cytogenetic remission at a median follow-up of 7 months and a major molecular remission (BCR-ABL/ABLo0,12%) at a median follow-up of 20 months indicating thus the efficacy of imatinib mesylate in patients with rare BCR-ABL transcripts. The aggressive clinical course of these leukemias suggested previously could be shrouded by appropriate targeted therapy. The direct junction between exons e8 from BCR gene and a2 from ABL gene would generate a stop codon. The open reading frame was preserved either by insertion of intronic sequences from ABL gene, or either (in 3/11 cases described previously) with a break inside the exon e8 from BCR gene.
2 An interesting common feature was that in all cases described here (and in three previously reported patients, 2,4,5 which accounts for more than 50% of the e8a2 patients described to date and therefore could represent the most frequent rearrangement in e8a2 patients) molecular study showed an identical 55 bp
